Ironwood Pharmaceuticals Inc - Class A
Research Ironwood Pharmaceuticals Inc - Class A (IRWD) on Bullrun: valuation model: 26.2% undervalued, market cap USD 725.40M, P/E 5.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIRWD
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal26.2% undervalued
- Market capUSD 725.40M
- P/E5.7
- Financial periodQ2 2026
- RevenueUSD 113.04M
- Net incomeUSD 51.29M
- Free cash flowUSD 58.28M
Valuation Snapshot
Bullrun's latest valuation model marks Ironwood Pharmaceuticals Inc - Class A as 26.2% undervalued; latest market cap is USD 725.40M; P/E is 5.7.
Peer valuation comparison
Latest P/E is 5.73x versus a Healthcare sector median of 24.46x (76.6% below).
Latest P/E is 5.73x versus a United States median of 24.87x (77.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 296.15M | USD 24.02M | USD 127.01M | n/a | 0.15 | USD 215.46M | USD 597.80M | -USD 261.84M |
| FY2024 | USD 351.41M | USD 880.00K | USD 103.41M | n/a | 0.01 | USD 88.56M | USD 198.99M | -USD 301.34M |
| FY2023 | USD 442.74M | -USD 1.03B | USD 183.15M | n/a | -6.45 | USD 92.15M | USD 397.87M | -USD 346.30M |
| FY2022 | USD 410.60M | USD 175.07M | USD 273.63M | n/a | 0.96 | USD 656.20M | USD 396.25M | USD 652.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 725.40M | 5.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 549.51M | 28.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 709.71M | 443.0 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.79B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.90B | 13.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.89B | 3.6 | n/a | n/a |
About Ironwood Pharmaceuticals Inc - Class A
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Ironwood Pharmaceuticals Inc - Class A overvalued or undervalued?
Bullrun's valuation model currently marks Ironwood Pharmaceuticals Inc - Class A as 26.2% undervalued.
What is Ironwood Pharmaceuticals Inc - Class A's market cap?
Ironwood Pharmaceuticals Inc - Class A's market capitalization is USD 725.40M.
What is Ironwood Pharmaceuticals Inc - Class A's P/E ratio?
Ironwood Pharmaceuticals Inc - Class A's price-to-earnings (P/E) ratio is 5.7.
What does Ironwood Pharmaceuticals Inc - Class A do?
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.